ACC 2026 Scientific sessions, March 29, 2026)
ACC 2026 Scientific sessions, March 29, 2026)
SPIRIT-HF: No Clear Benefit of Spironolactone in HFpEF/HFmrEF
• CV death + HF hospitalization
No difference vs placebo
But…
• Trial underpowered (~50% enrollment)
• High discontinuation
https://www.tctmd.com/news/
